Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the safety profile of bevacizumab when combined with standard chemotherapy as first-line treatment of advanced or recurrent non-squamous NSCLC. In particular, the incidence of serious adverse events (SAEs) related to bevacizumab and the incidence of specific AEs (serious and non-serious) such as hypertension, proteinuria, wound healing complications, gastrointestinal perforations, arterial and venous thomboembolic events, haemoptysis, CNS bleeding, other haemorrhages and CHF will be investigated.
Inclusion criteria
- Advanced or recurrent non-squamous non-small cell lung cancer